Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 11/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408517 | 0.87 | CHRM3 (0.48) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL14408506 | 0.82 | CHRM3 (0.38) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL11881887 | 0.82 | ALDH1A1 (0.39) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL73892 | 0.81 | DAO (0.45) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL73891 | 0.81 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GAAPOLB | |
| Bromomethane SCHEMBL5389919 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1GAAPOLB | |
| Iodomethane SCHEMBL6402613 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL14533674 | 0.79 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GAAPOLB | |
| SCHEMBL30990195 | 0.79 | CHRM3 (0.42) | CHRM3CHRM2CHRM1GAAPOLB | |
| Bromide SCHEMBL16713401 | 0.79 | DAO (0.43) | CHRM3CHRM2CHRM1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225395-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20140323732-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20130116435-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-05-09 | — | — | US | disclosed |
| US-8378103-B2 | Process for the preparation of tiotropium bromide | SICOR, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8344143-B2 | Process for the preparation of tiotropium bromide | SICOR, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100210844-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100105913-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100099867-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7662963-B2 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090247747-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20080051582-A1 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-RE39820-E1 | As anticholinergics, administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma; administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-04 | — | — | US | disclosed |
| US-RE39820-E1 | As anticholinergics, administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma; administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-04 | — | — | US | disclosed |
| US-20070027320-A1 | New Process for the Production of Tiotropium Salts | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323732-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | NR5A1, THOP1, CYP21A2 | CHRM3 39/4885CHRM2 47/4885CHRM1 17/4885 |
| US-20080051582-A1 | Process for the preparation of tiotropium bromide | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20090247747-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20130116435-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | NR5A1, THOP1, CYP21A2 | CHRM3 39/4885CHRM2 47/4885CHRM1 17/4885 |
| US-20100105913-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20100099867-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20070027320-A1 | New Process for the Production of Tiotropium Salts | NR5A1, THOP1, CYP21A2 | CHRM3 39/4885CHRM2 47/4885CHRM1 17/4885 |
| US-20100210844-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | NR5A1, THOP1, CYP21A2 | CHRM3 39/4885CHRM2 47/4885CHRM1 17/4885 |
| US-20150225395-A1 | NEW PROCESS FOR THE PRODUCTION OF TIOTROPIUM SALTS | NR5A1, THOP1, CYP21A2 | CHRM3 39/4885CHRM2 47/4885CHRM1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.